{"prompt": "['2014-0546', 'August 7, 2017', 'Page 7 of 49', 'Abbreviation', 'Definition', 'PP', 'Per protocol', 'PRBC', 'Packed red blood cells', 'PT', 'Preferred Term (MedDRA)', 'PV', 'Polycythemia vera', 'Q3W', 'Every 3 weeks', 'Q6W', 'Every 6 weeks', 'QC', 'Quality control', 'QOL', 'Quality of life', 'QW', 'Every week', 'RAEB, - -1, -2', 'Refractory anemia with excess blasts, -type 1, -type 2', 'RBC', 'Red blood cell', 'RBD', 'Ras binding domain', 'RPTD', 'Recommended Phase II dose', 'SADR', 'Serious adverse drug reaction', 'SAE', 'Serious adverse event', 'SC', 'Subcutaneous(ly)', 'SOC', 'System Organ Class (MedDRA)', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'Tmax', 'Time to maximum plasma concentration', 'TEAE', 'Treatment-emergent adverse event', 'TI', 'Transfusion independence', 'ULN', 'Upper limit of normal', 'US', 'United States', 'UTI', 'Urinary tract infection', 'WBC', 'White blood cell', 'WHO', 'World Health Organization']['2014-0546', 'August 7, 2017', 'Page 8 of 49', '1.', 'INTRODUCTION', '1.1.', 'Description of the Investigational Product', 'Rigosertib sodium (ON 01910.Na; rigosertib hereafter) is a first-in-class dual', 'phosphatidylinositol 3-kinase (PI3K)/polo-like kinase (PLK) pathway inhibitor that targets critical', 'signals involved in the growth and survival of cancer cells. At the molecular level, rigosertib acts', 'by selectively targeting 2 of the PI3K subunits (a and \u00df), while also inhibiting downstream signals', 'in the pathway such as the phosphorylation of serine-threonine kinase (AKT) and translation of', 'cyclin D1 (Prasad 2009, Olnes 2012). Rigosertib also acts by inhibiting the PLK pathway, leading', 'to a reduction in the activity of pro-mitotic proteins such as cell division cycle 25 (CDC25) and', 'cyclin-dependent kinase (CDK)/cyclin B (Jimeno 2010). The dual molecular mechanism of action', 'of rigosertib results in induction of multiple centrosomes during cell division, leading to multi-', 'polar spindle formation (Reddy 2008), total disorganization of the mitotic apparatus causing', 'chromosomal catastrophe (Reddy 2008), and modulation of the extracellular signal-regulated', 'kinase (ERK)/mitogen-activated protein kinase (MAPK) (growth) and AKT (survival) pathways,', 'promoting cell death (apoptosis) in cancer cells (Chapman 2012). Recent data suggest that', 'rigosertib binds to the Ras binding domain (RBD) of Ras effector proteins (ie, PI3K and Raf),', 'thereby leading to their inactivation (data on file). This novel mechanism may help explain the', 'multi-faceted effects of rigosertib, such as inhibition of the PI3K and PLK pathways.', 'Rigosertib was granted orphan drug status for the treatment of MDS by the Office of Orphan', 'Products Development (HF-35) at the Food & Drug Administration (FDA) on September 3, 2009', '(designation request #09-2894).', '1.2.', 'Summary of Clinical Findings Relevant to the Trial', 'Two formulations of rigosertib are currently being studied: intravenous (IV) and oral. At the time', \"of the latest compilation of information (Investigator's Brochure [IB] edition 21; Rigosertib IB),\", '1176 patients with either MDS or other hematologic malignancies (N = 661) or advanced cancer', 'and solid tumors (N = 515) were enrolled in 26 Phase I-III clinical studies of IV (N = 839) and', 'oral (N = 337) rigosertib conducted by Onconova. Six other Phase I studies of rigosertib in a', 'total of 51 patients with MDS and other hematologic malignancies were completed or are being', 'conducted by other Sponsors (NHLBI and SymBio Pharmaceuticals) under different INDs.', 'In Phase I/II studies of IV rigosertib in adult patients with MDS and acute myeloid leukemia', '(AML), rigosertib was administered as 2- to 6-day continuous intravenous (CIV) infusions.', 'Overall, rigosertib was reasonably well tolerated (see Rigosertib IB). Significant activity in', 'reducing bone marrow blasts (BMBL) was found to be correlated to overall survival (OS).']['2014-0546', 'August 7, 2017', 'Page 9 of 49', 'A Phase I dose escalation study of oral rigosertib in MDS patients was completed at Moffitt Cancer', 'Center and Columbia University Medical Center (#09-01). The study was divided into 3 parts:', 'Part I evaluated the bioavailability and tolerability of single oral doses (70 mg, 140 mg, 280 mg,', '560 mg, and 700 mg) administered weekly for 5 weeks. Part II (maximum tolerated dose [MTD]', 'evaluation) assessed the tolerability of the same oral escalating doses (ie, 70 mg, 140 mg, 280 mg,', '560 mg, and 700 mg), administered twice daily (BID) for 14 days of a 21-day cycle. Part III was', 'a confirmation of the recommended Phase II dose (RPTD) with absolute bioavailability and food', 'effect studies. Eligibility criteria included any International Prognostic Scoring System (IPSS)', 'MDS risk group with at least 1 cytopenia; failure to respond to at least 1 prior standard treatment;', 'Eastern Cooperative Oncology Group (ECOG) performance status 2; and adequate kidney and', 'liver functions. Key exclusion criteria included hypoplastic MDS (< 10% cellularity), ascites,', 'history of seizures, uncontrolled hypertension, and history of human immunodeficiency virus', '(HIV) infection. Dose-limiting toxicity (DLT) was defined as > Grade 3 non-hematologic drug-', 'related toxicity (based on National Cancer Institute [NCI] Common Terminology Criteria for', 'Adverse Events [CTCAE]) or delay in recovery of blood counts to Baseline levels for more than', '30 days in the absence of response. A total of 37 MDS patients were enrolled. Pharmacokinetic', '(PK) dose proportionality was established in the 70 mg to 700 mg single-dose range in the first', '3 patients enrolled, and pharmacodynamically active concentrations were reached. During the', 'subsequent escalation phase, the RPTD was identified as 560 mg BID.', 'Overall rigosertib capsules were reasonably well tolerated, with dysuria as the most frequent', 'treatment-emergent adverse event (TEAE). One patient on 700 mg experienced 2 DLTs (dysuria', 'and shortness of breath) during the first 3-week cycle. Another patient on 700 mg experienced', 'Grade 3 dysuria during Cycle 2.', 'Twelve patients in the confirming cohort underwent full PK evaluation (absolute bioavailability', 'vs. the IV formulation, and food effect). Following a single fasting dose, oral rigosertib was rapidly', 'absorbed (time to maximum plasma concentration [Tmax] ~ 1 hr). Systemic exposure, as', 'determined by maximum plasma concentration (Cmax) and the area under the plasma concentration-', 'time from 0 to infinity (AUC0-00), increased in a linear and dose-proportional manner over the dose', 'range of 70 mg to 700 mg. The plasma concentration-time profile exhibited a rapid distribution', 'phase followed by a slower elimination phase. The elimination half-life from plasma after oral', 'rigosertib dosing was comparable to estimates obtained after IV dosing. The absolute', 'bioavailability of rigosertib (560 mg dose) was 35%. Food significantly reduced the rate and extent', 'of rigosertib absorption. Oral administration of rigosertib after a meal decreased Cmax and AUC0-', '00 by 77% and 61%, respectively, compared to fasting conditions, with an estimated bioavailability', 'of 14%.', 'Encouraging signs of activity were observed. Two bone marrow complete responses (BMCR) were', 'observed in refractory anemia with excess blasts type 1 (RAEB-1) patients previously treated with', 'azacitidine (AZA) at the 140 mg and 560 mg dose levels. In addition, transitions to transfusion']\n\n###\n\n", "completion": "END"}